As expected, dapagliflozin caused people with type 2 diabetes to excrete much more sugar in their urine, which is how the drug works to lower blood sugar.
Scientific Claim
Dapagliflozin treatment was associated with a substantial increase in 24-hour urinary glucose excretion by 351 mmol/day (95% CI: 273 to 428) after 2-4 days and 322 mmol/day (95% CI: 231 to 413) after 12-14 days in patients with type 2 diabetes and preserved kidney function on a standardized sodium intake.
Original Statement
“Mean (SD) baseline urinary glucose excretion was 1.9 (2.2) mmol/24-h, which, as expected, significantly increased during dapagliflozin treatment (urinary glucose change at ST: 351 mmol/24-h [95% CI 273, 428; P < 0.0001]; change at ET: 322 mmol/24-h [231, 413; P < 0.0001])”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is nonrandomized and lacks a control group, so only association can be inferred. The claim correctly uses 'associated with' to reflect this limitation.